Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$3.17
+3.6%
$3.04
$2.18
$7.90
$32.93M0.7423,384 shs10,440 shs
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$5.73
+4.0%
$6.84
$3.80
$10.90
$23.92M-0.8316,264 shs1,634 shs
Marpai, Inc. stock logo
MRAI
Marpai
$1.35
-6.9%
$1.24
$0.40
$1.68
$22.32M4.7918,937 shs325 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.78
+1.7%
$4.84
$0.53
$5.25
$48.13M-1.689,383 shs395 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00%-16.16%-1.29%-29.56%-52.54%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00%-4.96%-20.23%+31.81%-41.73%
Marpai, Inc. stock logo
MRAI
Marpai
0.00%-2.88%+2.20%+32.35%+98.53%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-3.69%0.00%+18.39%+82.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.1775 of 5 stars
0.03.00.00.03.31.70.6
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/AN/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$70.67M0.48N/AN/A$7.39 per share0.43
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$52.60M0.47N/AN/A$51.05 per share0.11
Marpai, Inc. stock logo
MRAI
Marpai
$34.87M0.64N/AN/A($1.72) per share-0.78
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.00N/AN/A($11.55) per share-0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$47.49M-$1.89N/AN/A-45.41%-38.33%-25.34%N/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$42.23MN/A0.00N/AN/AN/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
-$28.75M-$1.82N/AN/A-85.70%N/A-100.23%8/5/2025 (Estimated)
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)

Latest MRAI, OPGN, BNR, and CCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/6/2025Q1 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.17N/A-$0.17N/A$18.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
Marpai, Inc. stock logo
MRAI
Marpai
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
3.02
2.76
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.67
0.46
0.45
Marpai, Inc. stock logo
MRAI
Marpai
N/A
0.82
0.82
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
Marpai, Inc. stock logo
MRAI
Marpai
49.75%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
Marpai, Inc. stock logo
MRAI
Marpai
61.30%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.50 millionNot Optionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
Marpai, Inc. stock logo
MRAI
Marpai
15016.53 million5.61 millionNo Data
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable

Recent News About These Companies

OpGen Forms Joint Venture with European Bank
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split
OpGen Announced 1-for-10 Reverse Stock Split

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$3.17 +0.11 (+3.63%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$5.73 +0.22 (+3.99%)
As of 03:51 PM Eastern

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Marpai stock logo

Marpai NASDAQ:MRAI

$1.35 -0.10 (-6.90%)
As of 01:19 PM Eastern

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.78 +0.08 (+1.70%)
As of 10:38 AM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.